Users most often reported increased appetite, unlike the stomach issues seen in trials. The authors say it proves nothing causal and only flags leads to test.
Recap by typeshit. Full story at University of Pennsylvania.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Federal health officials are pushing forward with a plan to open up access to injectable peptides, a drug class that remains unproven.
NPR counted about 2,000 pancreatitis cases among the suits, per a Facebook share of its reporting. The post is brief, so the fuller breakdown is at the source.
Loading…